These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17478147)

  • 1. Impact of the Food and Drug Administration's Public Health Notification on the adoption of drug-eluting stents.
    Curtis JP; Cohen DJ; Jones PG; Bach RG; Spertus JA; Krumholz HM
    Am J Cardiol; 2007 May; 99(9):1227-9. PubMed ID: 17478147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of drug-eluting stents in the coronary artery in ST-elevation myocardial infarction at a single high-volume medical center.
    Bose R; Gupta G; Grayburn PA; Laible EA; Kang MJ; Choi JW
    Am J Cardiol; 2007 Sep; 100(6):949-52. PubMed ID: 17826375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.
    Simonton CA; Brodie B; Cheek B; Krainin F; Metzger C; Hermiller J; Juk S; Duffy P; Humphrey A; Nussbaum M; Laurent S;
    J Am Coll Cardiol; 2007 Sep; 50(13):1214-22. PubMed ID: 17888837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical results of drug eluting stents compared to bare metal stents for patients with ST elevation acute myocardial infarction.
    Kornowski R; Vaknin-Assa H; Lev E; Ben-Dor I; Teplitsky I; Rechavia E; Brosh D; Fuchs S; Assali A
    Acute Card Care; 2008; 10(3):167-72. PubMed ID: 18803074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
    Kaltoft A; Jensen LO; Maeng M; Tilsted HH; Thayssen P; Bøttcher M; Lassen JF; Krusell LR; Rasmussen K; Hansen KN; Pedersen L; Johnsen SP; Sørensen HT; Thuesen L
    J Am Coll Cardiol; 2009 Feb; 53(8):658-64. PubMed ID: 19232897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction.
    Ting HH; Roe MT; Gersh BJ; Spertus JA; Rumsfeld JS; Ou FS; Kao J; Long KH; Holmes DR; Peterson ED;
    Am J Cardiol; 2008 Feb; 101(3):286-92. PubMed ID: 18237586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients.
    Romagnoli E; Leone AM; Burzotta F; Trani C; Angeloni G; Materazzo G; Niccoli G; De Vita M; Perfetti M; Mazzari MA; Mongiardo R; Rebuzzi AG; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2008 Jun; 9(6):589-94. PubMed ID: 18475127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry.
    Daemen J; Kukreja N; van Twisk PH; Onuma Y; de Jaegere PP; van Domburg R; Serruys PW
    Am J Cardiol; 2008 Apr; 101(8):1105-11. PubMed ID: 18394442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
    Marzocchi A; Saia F; Piovaccari G; Manari A; Aurier E; Benassi A; Cremonesi A; Percoco G; Varani E; Magnavacchi P; Guastaroba P; Grilli R; Maresta A
    Circulation; 2007 Jun; 115(25):3181-8. PubMed ID: 17562952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry.
    Ortolani P; Balducelli M; Marzaroli P; Piovaccari G; Menozzi A; Guiducci V; Sangiorgio P; Tarantino F; Geraci G; Castriota F; Tondi S; Saia F; Cooke RM; Guastaroba P; Grilli R; Marzocchi A; Maresta A
    Circulation; 2008 Feb; 117(7):923-30. PubMed ID: 18250265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical appraisal of the safety and efficacy of drug-eluting stents.
    Maluenda G; Lemesle G; Waksman R
    Clin Pharmacol Ther; 2009 May; 85(5):474-80. PubMed ID: 19279567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term (>3 Years) outcome and predictors of clinical events after insertion of sirolimus-eluting stent in one or more native coronary arteries (from the Israeli arm of the e-Cypher registry).
    Planer D; Beyar R; Almagor Y; Banai S; Guetta V; Miller H; Kornowski R; Brandes S; Krakover R; Solomon M; Lotan C
    Am J Cardiol; 2008 Apr; 101(7):953-9. PubMed ID: 18359314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study).
    Patel MR; Pfisterer ME; Betriu A; Widmisky P; Holmes DR; O'Neill WW; Stebbins A; Van de Werf F; Armstrong PW; Granger CB;
    Am J Cardiol; 2009 Jan; 103(2):181-6. PubMed ID: 19121433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.
    Roy P; Buch AN; Javaid A; Okabe T; Raya V; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Gevorkian N; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Feb; 101(3):293-9. PubMed ID: 18237587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction.
    Slottow TL; Steinberg DH; Roy P; Javaid A; Buch AN; Okabe T; Xue Z; Smith K; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Waksman R
    Cardiovasc Revasc Med; 2008; 9(1):24-8. PubMed ID: 18206634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of serolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction patients: a meta-analysis.
    Pan XH; Zhong WZ; Xiang MX; Xu G; Shan J; Wang JA
    Chin Med J (Engl); 2009 Jan; 122(1):88-92. PubMed ID: 19187623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.
    De Felice F; Fiorilli R; Parma A; Menichelli M; Nazzaro MS; Pucci E; Dibra A; Musto C; Violini R
    Int J Cardiol; 2009 Mar; 132(3):337-41. PubMed ID: 18234373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.